Report Cover

Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market 2020 by Company, Regions, Type and Application, Forecast to 2025


Market Overview
The global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.6% in the forecast period of 2020 to 2025 and will expected to reach USD 6615.9 million by 2025, from USD 5125 million in 2019.

The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market has been segmented into:
    PCR
    In-situ Hybridization
    Immunohistochemistry
    Sequencing
    Others

By Application, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) has been segmented into:
    Oncology
    Neurological Disorders
    Cardiovascular Disease
    Immunological Disorders
    Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market presented in the report. This section sheds light on the sales growth of different regional and country-level Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market.

The report offers in-depth assessment of the growth and other aspects of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market in important countries (regions), including:
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia and Italy)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
    South America (Brazil, Argentina, Colombia)
    Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share Analysis
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) sales, revenue and market share for each player covered in this report.

The major players covered in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) are:
    Qiagen NV
    Pfizer
    F Hoffman La Roche
    GE Healthcare
    Leica Biosystems Nussloch GmBH
    Agilent Technologies
    Thermo Fisher Scientific Inc.
    Foundation Medicine
Table of Contents

1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Overview
    1.1 Product Overview and Scope of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)
    1.2 Classification of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Type
        1.2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Type: 2015 VS 2019 VS 2025
        1.2.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Type in 2019
        1.2.3 PCR
        1.2.4 In-situ Hybridization
        1.2.5 Immunohistochemistry
        1.2.6 Sequencing
        1.2.7 Others
    1.3 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market by Application
        1.3.1 Overview: Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Application: 2015 VS 2019 VS 2025
        1.3.2 Oncology
        1.3.3 Neurological Disorders
        1.3.4 Cardiovascular Disease
        1.3.5 Immunological Disorders
        1.3.6 Others
    1.4 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market by Regions
        1.4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions: 2015 VS 2019 VS 2025
        1.4.2 Global Market Size of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) (2015-2025)
        1.4.3 North America (USA, Canada and Mexico) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
        1.4.4 Europe (Germany, France, UK, Russia and Italy) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
        1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
        1.4.6 South America (Brazil, Argentina, Colombia) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
        1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
2 Company Profiles
    2.1 Qiagen NV
        2.1.1 Qiagen NV Details
        2.1.2 Qiagen NV Major Business and Total Revenue (Financial Highlights) Analysis
        2.1.3 Qiagen NV SWOT Analysis
        2.1.4 Qiagen NV Product and Services
        2.1.5 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
    2.2 Pfizer
        2.2.1 Pfizer Details
        2.2.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
        2.2.3 Pfizer SWOT Analysis
        2.2.4 Pfizer Product and Services
        2.2.5 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
    2.3 F Hoffman La Roche
        2.3.1 F Hoffman La Roche Details
        2.3.2 F Hoffman La Roche Major Business and Total Revenue (Financial Highlights) Analysis
        2.3.3 F Hoffman La Roche SWOT Analysis
        2.3.4 F Hoffman La Roche Product and Services
        2.3.5 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
    2.4 GE Healthcare
        2.4.1 GE Healthcare Details
        2.4.2 GE Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
        2.4.3 GE Healthcare SWOT Analysis
        2.4.4 GE Healthcare Product and Services
        2.4.5 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
    2.5 Leica Biosystems Nussloch GmBH
        2.5.1 Leica Biosystems Nussloch GmBH Details
        2.5.2 Leica Biosystems Nussloch GmBH Major Business and Total Revenue (Financial Highlights) Analysis
        2.5.3 Leica Biosystems Nussloch GmBH SWOT Analysis
        2.5.4 Leica Biosystems Nussloch GmBH Product and Services
        2.5.5 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
    2.6 Agilent Technologies
        2.6.1 Agilent Technologies Details
        2.6.2 Agilent Technologies Major Business and Total Revenue (Financial Highlights) Analysis
        2.6.3 Agilent Technologies SWOT Analysis
        2.6.4 Agilent Technologies Product and Services
        2.6.5 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
    2.7 Thermo Fisher Scientific Inc.
        2.7.1 Thermo Fisher Scientific Inc. Details
        2.7.2 Thermo Fisher Scientific Inc. Major Business and Total Revenue (Financial Highlights) Analysis
        2.7.3 Thermo Fisher Scientific Inc. SWOT Analysis
        2.7.4 Thermo Fisher Scientific Inc. Product and Services
        2.7.5 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
    2.8 Foundation Medicine
        2.8.1 Foundation Medicine Details
        2.8.2 Foundation Medicine Major Business and Total Revenue (Financial Highlights) Analysis
        2.8.3 Foundation Medicine SWOT Analysis
        2.8.4 Foundation Medicine Product and Services
        2.8.5 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
    3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Share by Players (2015-2020)
    3.2 Market Concentration Rate
        3.2.1 Top 5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players Market Share
        3.2.2 Top 10 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players Market Share
    3.3 Market Competition Trend
4 Market Size by Regions
    4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Market Share by Regions
    4.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    4.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    4.4 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    4.5 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    4.6 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
5 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries
    5.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
    5.2 USA Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    5.3 Canada Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    5.4 Mexico Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
6 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries
    6.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
    6.2 Germany Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    6.3 UK Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    6.4 France Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    6.5 Russia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    6.6 Italy Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries
    7.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
    7.2 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    7.3 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    7.4 Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    7.5 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    7.6 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
8 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries
    8.1 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
    8.2 Brazil Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    8.3 Argentina Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Countries
    9.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
    9.2 Saudi Arabia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    9.3 UAE Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    9.4 Egypt Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
    9.5 South Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
    10.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Market Share by Type (2015-2020)
    10.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Type (2019-2024)
    10.3 PCR Revenue Growth Rate (2015-2025)
    10.4 In-situ Hybridization Revenue Growth Rate (2015-2025)
    10.5 Immunohistochemistry Revenue Growth Rate (2015-2025)
    10.6 Sequencing Revenue Growth Rate (2015-2025)
    10.7 Others Revenue Growth Rate (2015-2025)
11 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Segment by Application
    11.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Application (2015-2020)
    11.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Application (2019-2024)
    11.3 Oncology Revenue Growth (2015-2020)
    11.4 Neurological Disorders Revenue Growth (2015-2020)
    11.5 Cardiovascular Disease Revenue Growth (2015-2020)
    11.6 Immunological Disorders Revenue Growth (2015-2020)
    11.7 Others Revenue Growth (2015-2020)
12 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Forecast (2021-2025)
    12.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Forecast (2021-2025)
    12.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Regions (2021-2025)
    12.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
    12.4 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
    12.5 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
    12.6 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
    12.7 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
    14.1 Methodology
    14.2 Data Source
    14.3 Disclaimer
    14.4 About US

List of Tables Table 1. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million) by Type: 2015 VS 2019 VS 2025 Table 2. Breakdown of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Company Type (Tier 1, Tier 2 and Tier 3) Table 3. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million) by Application: 2015 VS 2019 VS 2025 Table 4. Global Market Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) Comparison by Regions 2015-2025 Table 5. Qiagen NV Corporate Information, Location and Competitors Table 6. Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business Table 7. Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018) Table 8. Qiagen NV SWOT Analysis Table 9. Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions Table 10. Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019) Table 11. Pfizer Corporate Information, Location and Competitors Table 12. Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business Table 13. Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2018-2019) Table 14. Pfizer SWOT Analysis Table 15. Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions Table 16. Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019) Table 17. F Hoffman La Roche Corporate Information, Location and Competitors Table 18. F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business Table 19. F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018) Table 20. F Hoffman La Roche SWOT Analysis Table 21. F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions Table 22. F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019) Table 23. GE Healthcare Corporate Information, Location and Competitors Table 24. GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business Table 25. GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018) Table 26. GE Healthcare SWOT Analysis Table 27. GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions Table 28. GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019) Table 29. Leica Biosystems Nussloch GmBH Corporate Information, Location and Competitors Table 30. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business Table 31. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018) Table 32. Leica Biosystems Nussloch GmBH SWOT Analysis Table 33. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions Table 34. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019) Table 35. Agilent Technologies Corporate Information, Location and Competitors Table 36. Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business Table 37. Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018) Table 38. Agilent Technologies SWOT Analysis Table 39. Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions Table 40. Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019) Table 41. Thermo Fisher Scientific Inc. Corporate Information, Location and Competitors Table 42. Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business Table 43. Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018) Table 44. Thermo Fisher Scientific Inc. SWOT Analysis Table 45. Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions Table 46. Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019) Table 47. Foundation Medicine Corporate Information, Location and Competitors Table 48. Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business Table 49. Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018) Table 50. Foundation Medicine SWOT Analysis Table 51. Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions Table 52. Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019) Table 53. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Players (2015-2020) Table 54. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Players (2015-2020) Table 55. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Regions (2015-2020) Table 56. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Regions (2015-2020) Table 57. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020) Table 58. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020) Table 59. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Countries (2015-2020) Table 60. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Countries (2015-2020) Table 61. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020) Table 62. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020) Table 63. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Countries (2015-2020) Table 64. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020) Table 65. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Type (2015-2020) Table 66. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Type (2015-2020) Table 67. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Forecast by Type (2021-2025) Table 68. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Application (2015-2020) Table 69. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Application (2015-2020) Table 70. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Forecast by Application (2021-2025) Table 71. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) Forecast by Regions (2021-2025) List of Figures Figure 1. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Picture Figure 2. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Type in 2019 Figure 3. PCR Picture Figure 4. In-situ Hybridization Picture Figure 5. Immunohistochemistry Picture Figure 6. Sequencing Picture Figure 7. Others Picture Figure 8. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Application in 2019 Figure 9. Oncology Picture Figure 10. Neurological Disorders Picture Figure 11. Cardiovascular Disease Picture Figure 12. Immunological Disorders Picture Figure 13. Others Picture Figure 14. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2015-2025) Figure 15. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025) Figure 16. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025) Figure 17. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025) Figure 18. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025) Figure 19. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025) Figure 20. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025) Figure 21. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Players in 2019 Figure 22. Global Top 5 Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share in 2019 Figure 23. Global Top 10 Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share in 2019 Figure 24. Key Players Market Share Trend Figure 25. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (%) (2015-2020) Figure 26. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Regions (2015-2020) Figure 27. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Regions in 2018 Figure 28. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 29. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 30. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 31. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 32. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 33. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020) Figure 34. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries in 2019 Figure 35. USA Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 36. Canada Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 37. Mexico Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 38. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020) Figure 39. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries in 2019 Figure 40. Germany Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 41. UK Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 42. France Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 43. Russia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 44. Italy Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 45. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020) Figure 46. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries in 2019 Figure 47. China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 48. Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 49. Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 50. India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 51. Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 52. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020) Figure 53. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries in 2019 Figure 54. Brazil Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 55. Argentina Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 56. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020) Figure 57. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries in 2019 Figure 58. Saudi Arabia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 59. UAE Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 60. Egypt Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 61. South Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020) Figure 62. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Type (2015-2020) Figure 63. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Type in 2019 Figure 64. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share Forecast by Type (2021-2025) Figure 65. Global PCR Revenue Growth Rate (2015-2020) Figure 66. Global In-situ Hybridization Revenue Growth Rate (2015-2020) Figure 67. Global Immunohistochemistry Revenue Growth Rate (2015-2020) Figure 68. Global Sequencing Revenue Growth Rate (2015-2020) Figure 69. Global Others Revenue Growth Rate (2015-2020) Figure 70. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Application (2015-2020) Figure 71. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Application in 2019 Figure 72. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share Forecast by Application (2021-2025) Figure 73. Global Oncology Revenue Growth Rate (2015-2020) Figure 74. Global Neurological Disorders Revenue Growth Rate (2015-2020) Figure 75. Global Cardiovascular Disease Revenue Growth Rate (2015-2020) Figure 76. Global Immunological Disorders Revenue Growth Rate (2015-2020) Figure 77. Global Others Revenue Growth Rate (2015-2020) Figure 78. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate Forecast (2021-2025) Figure 79. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) Forecast by Regions (2021-2025) Figure 80. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share Forecast by Regions (2021-2025) Figure 81. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025) Figure 82. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025) Figure 83. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025) Figure 84. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025) Figure 85. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025) Figure 86. Sales Channel: Direct Channel vs Indirect Channel

Qualitative Analysis covers:

  • Industry Status and Trends
  • Manufacturer/Company profiles, manufacturing base distribution, sales areas, product introduction, main business, market position and their competitors.
  • Product Development, Technology, Price, Cost, Manufacturing Process and Trends
  • Market segment by regions, types, applications and forecast
  • Market opportunities, potential, government policies and influence factors.
     

Quantitative Analysis covers:

  • Market size (value, sales/output, historical data and forecasts)
  • Sales/output/capacity, revenue, price, gross margin, market share, for top players. Through interviewing each manufacturers,  distributors, traders, dealers and buyers etc.
  • Cost structure, proportion, price trend, gross margin and trend, status and trend, for 10 years
  • Market size by types, regions, applications for 10 years
  • Market forecast based on the potential demand from downstream clients/buyers, government, influence factors and the total economic indication, maybe occur in following years.
     

Data Sources:

Methodology

 

New Pharmaceuticals and Healthcare Reports

Internal Neuromodulation Market Forecast 2025 | Global Report

Rising number of patients suffering from neurological disorders such as Parkinson’s, essential tremor, and primary dystonia is fueling the demand for internal neuromodulation procedures. Chronic back and leg pain associated with PVD (peripheral...

Gastrointestinal Cancer Treatment Market Size 2020-2025 | Growth Forecasts

As per credible projections, gastrointestinal cancer treatment industry is expected to register strong CAGR over 2019-2025. Rising adoption of unhealthy eating habits and increasing consumption of tobacco and alcohol have increased the pervasiveness ...

Topotecan Hydrochloride Market Trends and Research Insights by 2025

As per credible estimates, global topotecan hydrochloride market is poised to acquire commendable gains by the year 2025. Rising adoption of unhealthy and sedentary lifestyle has increased the pervasiveness of small cell lung cancer, ovarian cancer, ...

Flu Vaccine Market Share 2020-2025 | Global Industry Report

As per trusted estimates, global flu vaccine market will record substantial growth during 2020-2025. Increasing government initiatives to ensure the safety of the populace, minimal side-effects associated with influenza vaccines, improving efficacy o...

Healthcare Linen Market Size - Industry Trends Report 2025

According to reliable projections, global healthcare linen market is projected to record considerable growth during 2020-2025. Rising prevalence of various diseases including cardiovascular diseases, cancer, and arthritis along with increasing cases ...

Other Reports by GlobalInfoResearch

Global Active Infrared Detector Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

Market Overview The global Active Infrared Detector market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, fr...

Global Automobile Piston Pin Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

Market Overview The global Automobile Piston Pin market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from ...

Global Chemical Filter Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

Market Overview The global Chemical Filter market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx...

Global Switch Transistor Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

Market Overview The global Switch Transistor market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD ...

Global Neodymium-iron-boron Permanent Magnet Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

Market Overview The global Neodymium-iron-boron Permanent Magnet market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx millio...

Publisher: GlobalInfoResearch
Chat with us